New Blood Tests Approved for Lupus, Systemic Sclerosis Diagnoses New Blood Tests Approved for Lupus, Systemic Sclerosis Diagnoses
The Food and Drug Administration has approved a new diagnostic blood test to detect monospecific Ribosomal P antibodies to support a diagnosis of systemic lupus erythematosus.WebMD Health News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 17, 2022 Category: Pathology Tags: Rheumatology News Source Type: news

Non-Pharmacological Treatment of Systemic Sclerosis Symptoms Non-Pharmacological Treatment of Systemic Sclerosis Symptoms
This article provides evidence-based recommendations.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Testing for Th/To Antibodies May Help in Scleroderma Management
(MedPage Today) -- Detection of certain auto-antibodies flagged patients with scleroderma (also known as systemic sclerosis) who were especially likely to develop pulmonary hypertension over long-term follow-up, a single-center study indicated... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 25, 2022 Category: Cardiology Source Type: news

Cytokine Signatures Differentiate Systemic Sclerosis for PAH Cytokine Signatures Differentiate Systemic Sclerosis for PAH
Find out how serum cytokine signatures could help identify which systemic sclerosis patients are most at risk for pulmonary arterial hypertension.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 18, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

IV Prostanoids in Systemic Sclerosis-Associated PAH IV Prostanoids in Systemic Sclerosis-Associated PAH
What role could IV prostanoid therapy have in the treatment of systemic sclerosis-associated pulmonary arterial hypertension?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news

What's the Evidence Base for Prescribing New SSc-ILD Drugs? What's the Evidence Base for Prescribing New SSc-ILD Drugs?
Two experts from Hospital for Special Surgery review the evidence for how best to use nintedanib, tocilizumab, and combination therapy in treating patients with systemic sclerosis –associated ILD.Hospital for Special Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2022 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

Sepsis Mortality Is high in Patients With Connective Tissue Diseases Admitted to the Intensive Care Unit (ICU).
Conclusions: In-hospital sepsis mortality is high in CTD patients. SSc diagnoses and SOFA were independently associated with mortality. Additionally, common ICU scores were good predictors for mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 10, 2022 Category: Consumer Health News Source Type: news

EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
The recommendations advise on managing cardiovascular health in patients with gout, vasculitis, systemic sclerosis, myositis, Sj ögren syndrome, lupus, antiphospholipid syndrome, and other diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 24, 2022 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Anti-RNPV-3 Predicts Prognosis in Systemic Sclerosis ILD Anti-RNPV-3 Predicts Prognosis in Systemic Sclerosis ILD
What could anti-RNPC-3 antibodies tell us about outcomes in systemic sclerosis-associated lung disease?Rheumatology (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - February 16, 2022 Category: Transplant Surgery Tags: Radiology Journal Article Source Type: news

Real-World Data Back Stem Cell Transplant for Systemic Sclerosis Real-World Data Back Stem Cell Transplant for Systemic Sclerosis
In real-world study, stem cell transplant provides major advantages for rapidly progressive systemic sclerosis if strict selection criteria are used.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 8, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news

U.S. FDA Approves New MENTOR ® MemoryGel BOOST™ Breast Implant
Irvine, Calif., (January 13, 2021) – Mentor Worldwide LLC, the number one global brand in breast aesthetics, and part of the Johnson & Johnson Medical Devices Companies** today announced that the U.S. Food and Drug Administration (FDA) approved the MENTOR® MemoryGel BOOST™ Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for surgeons in the United States in early 2022. Nearly 400,000 women undergo breast implant surgeries every year in the U.S.[1], and selecting an implant is a very persona...
Source: Johnson and Johnson - January 13, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Systemic sclerosis a significant patient and health resource economic burden
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news

Rituximab Improves Systemic Sclerosis Skin, Lung Symptoms Rituximab Improves Systemic Sclerosis Skin, Lung Symptoms
Patients who took rituximab in the DESIRES trial had better skin scores and lung function at 6 months than did patients who received placebo.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news